indazoles has been researched along with Mammary Analogue Secretory Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florou, V; Garrido-Laguna, I; Gilcrease, GW; Maeda, P; Nevala-Plagemann, C; Whisenant, J | 1 |
| Arcila, M; Bauer, T; Berger, M; Cam, NR; Christiansen, J; Dogan, S; Drilon, A; Farago, A; Ghossein, R; Gounder, M; Hechtman, J; Ho, AL; Hornby, Z; Hyman, DM; Katabi, N; Ladanyi, M; Li, G; Lim, J; Liu, SV; Luo, D; Maneval, EC; Multani, P; Ou, SH; Patel, M; Shaw, A; Shen, R; Shoemaker, RF; Wang, L; Wei, G | 1 |
2 other study(ies) available for indazoles and Mammary Analogue Secretory Carcinoma
| Article | Year |
|---|---|
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Topics: Aza Compounds; Benzamides; Drug Resistance, Neoplasm; Humans; Indazoles; Mammary Analogue Secretory Carcinoma; Oncogene Proteins, Fusion; Parotid Gland; Protein Kinase Inhibitors; Salivary Gland Neoplasms | 2021 |
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Topics: Adult; Benzamides; Biomarkers, Tumor; Carcinoma, Acinar Cell; Clinical Trials as Topic; Crizotinib; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mammary Analogue Secretory Carcinoma; Mutation; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Salivary Gland Neoplasms | 2016 |